Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Bone Marrow Transplant ; 31(10): 927-30, 2003 May.
Artículo en Inglés | MEDLINE | ID: mdl-12748671

RESUMEN

The so-called pinch-off syndrome is observed in up to 1% of all central venous catheters (CVCs), and is a valuable warning prior to fragmentation, which occurs in approximately 40% of the respective cases. As long-term indwelling CVCs are used with increasing frequency, this paper describes the necessity of pinch-off monitoring following the experiences of a case study and a review of the current literature on this specific topic in order to point out preventive practice guidelines. Besides easy preventive practices such as a high level of suspicion and adequate X-ray controls, findings give strong evidence that the most important specific factor might be the adequate approach. In our hands, the supraclavicular technique has provided the best results with regards to percutaneous introduction of large bore CVCs.


Asunto(s)
Cateterismo Venoso Central/efectos adversos , Falla de Equipo , Adolescente , Trasplante de Médula Ósea , Femenino , Humanos , Monitoreo Fisiológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Radiografía Torácica , Trasplante Autólogo
2.
Br J Cancer ; 88(4): 496-501, 2003 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-12592361

RESUMEN

A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen. Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier's method. A total of 268 (range 1-8, median: 5) cycles were administered. Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months. The 6-month progression-free survival is 54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.


Asunto(s)
Dacarbazina/efectos adversos , Dacarbazina/uso terapéutico , Glioblastoma/diagnóstico , Glioblastoma/tratamiento farmacológico , Compuestos de Nitrosourea/efectos adversos , Compuestos de Nitrosourea/uso terapéutico , Compuestos Organofosforados/efectos adversos , Compuestos Organofosforados/uso terapéutico , Adolescente , Adulto , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis de Supervivencia , Tasa de Supervivencia
3.
Onkologie ; 24(4): 376-9, 2001 Aug.
Artículo en Alemán | MEDLINE | ID: mdl-11574766

RESUMEN

Multimodal Therapy of High Grade Gliomas in Adults For chemotherapy of high-grade gliomas only few substances with proven efficacy are available. Today, even the newest substances are not proven to be superior to nitrosoureas. Although nitrosoureas are still considered as commonly accepted standard treatment, these results are based on studies in which response evaluation was not performed according to standardized criteria: prognostic criteria were not taken into account and statistical power of these studies is limited. However, a lot of questions remain to be dealt with and are currently under investigation in multicentric randomized studies. Therefore, patients should be encouraged to participate in prospectively randomized trials. With or after chemotherapy, supportive and palliative care including neurorehabilitation are important to improve patients' quality of life.


Asunto(s)
Antineoplásicos/uso terapéutico , Glioma/tratamiento farmacológico , Antineoplásicos/efectos adversos , Quimioterapia Adyuvante , Terapia Combinada , Glioma/mortalidad , Glioma/radioterapia , Humanos , Radioterapia Adyuvante , Ensayos Clínicos Controlados Aleatorios como Asunto , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...